DrugPatentWatch Database Preview
Drugs in Development Information for N,N-Dimethyltryptamine
» See Plans and Pricing
What is the development status for investigational drug N,N-Dimethyltryptamine?
N,N-Dimethyltryptamine is an investigational drug.
There have been 6 clinical trials for N,N-Dimethyltryptamine.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are Depression, Alcoholism, and Alcohol Drinking. The leading clinical trial sponsors are Heffter Research Institute, Johns Hopkins University, and Beckley Foundation.
There are one hundred and fifty US patents protecting this investigational drug and eight hundred and seventy-five international patents.
Summary for N,N-Dimethyltryptamine
US Patents | 150 |
International Patents | 875 |
US Patent Applications | 412 |
WIPO Patent Applications | 199 |
Japanese Patent Applications | 58 |
Clinical Trial Progress | Phase 1 (2020-12-01) |
Vendors | 27 |
Recent Clinical Trials for N,N-Dimethyltryptamine
Title | Sponsor | Phase |
---|---|---|
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder | Johns Hopkins University | Phase 2 |
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors | Heffter Research Institute | Phase 1 |
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors | River Styx Foundation | Phase 1 |
Clinical Trial Summary for N,N-Dimethyltryptamine
Top disease conditions for N,N-Dimethyltryptamine
Top clinical trial sponsors for N,N-Dimethyltryptamine
US Patents for N,N-Dimethyltryptamine
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
N,N-Dimethyltryptamine | Start Trial | Methods of improving behavioral therapies | Emory University (Atlanta, GA) | Start Trial |
N,N-Dimethyltryptamine | Start Trial | Complex and structurally diverse compounds | The Board of Trustees of the University of Illinois (Urbana, IL) | Start Trial |
N,N-Dimethyltryptamine | Start Trial | Factor XIa inhibitors | Merck Sharp & Dohme Corp. (Rahway, NJ) | Start Trial |
N,N-Dimethyltryptamine | Start Trial | Pharmaceutical compositions resistant to abuse | EGALET LTD. (London, GB) | Start Trial |
N,N-Dimethyltryptamine | Start Trial | Formulations of histone deacetylase inhibitor and uses thereof | Pharmacyclics LLC (Sunnyvale, CA) | Start Trial |
N,N-Dimethyltryptamine | Start Trial | Methods, devices and systems for pulmonary delivery of active agents | Syqe Medical Ltd. (Tel-Aviv, IL) | Start Trial |
N,N-Dimethyltryptamine | Start Trial | Abuse-deterrent controlled release formulations | Patheon Softgels Inc. (High Point, NC) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for N,N-Dimethyltryptamine
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
N,N-Dimethyltryptamine | World Intellectual Property Organization (WIPO) | WO2013142873 | 2032-03-23 | Start Trial |
N,N-Dimethyltryptamine | European Patent Office | EP3134408 | 2034-04-22 | Start Trial |
N,N-Dimethyltryptamine | World Intellectual Property Organization (WIPO) | WO2015164308 | 2034-04-22 | Start Trial |
N,N-Dimethyltryptamine | Australia | AU2010211376 | 2029-02-06 | Start Trial |
N,N-Dimethyltryptamine | Australia | AU2013257533 | 2029-02-06 | Start Trial |
N,N-Dimethyltryptamine | Canada | CA2751627 | 2029-02-06 | Start Trial |
N,N-Dimethyltryptamine | Denmark | DK2393487 | 2029-02-06 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |